dalteparin has been researched along with melagatran in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 15 (93.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlsson, S; Eriksson, BI; Halvarsson, M; Mattsson, C; Risberg, B | 1 |
| Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P | 1 |
| Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K | 1 |
| Carlsson, S; Elg, M; Mattsson, C | 1 |
| Bergqvist, D; Bylock, A; Dahl, OE; Eriksson, BI; Eriksson, UG; Frison, L; Gustafsson, D; Kälebo, P; Lindbratt, S; Welin, L | 1 |
| Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N | 1 |
| Mattsson, C; Nylander, S | 1 |
| Boström, SL; Hansson, GF; Kjaer, M; Sarich, TC | 1 |
| Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N | 1 |
| Evans, HC; Faulds, D; Perry, CM | 1 |
| Agnelli, G; Andersson, M; Cohen, A; Dahl, O; Eriksson, BI; Mouret, P; Panfilov, S; Rosencher, N | 1 |
| Cimminiello, C; Planès, A; Samama, MM | 1 |
| Attman, PO; Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Ottosson, P; Samuelsson, O | 1 |
| Agnelli, G; Andersson, M; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Mouret, P; Ogren, M; Panfilov, S; Rosencher, N | 1 |
| Hamner, CE; Lewin, M; Potter, DD; Schaff, HV; Sundt, TM; Thompson, JL | 1 |
1 review(s) available for dalteparin and melagatran
| Article | Year |
|---|---|
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Venous Thrombosis; Warfarin | 2004 |
9 trial(s) available for dalteparin and melagatran
| Article | Year |
|---|---|
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in
Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Female; Glycine; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Postoperative Complications; Prodrugs; Safety; Sweden; Thrombin; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2002 |
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; DNA Mutational Analysis; Double-Blind Method; Europe; Factor V; Female; Genetic Predisposition to Disease; Genotype; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Promoter Regions, Genetic; Prospective Studies; Prothrombin; Pulmonary Embolism; Risk Factors; Thrombophilia; Venous Thrombosis | 2002 |
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Prodrugs; Thromboembolism | 2002 |
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Prodrugs; Prospective Studies; Pulmonary Embolism; Safety; Thrombin; Treatment Outcome; Venous Thrombosis | 2003 |
Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Factor Xa Inhibitors; Glycine; Humans; Inhibitory Concentration 50; Injections, Subcutaneous; Male; Reference Values; Thrombin; Time Factors; Veins | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Double-Blind Method; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Male; Middle Aged; Preoperative Care; Therapeutic Equivalency; Thrombin; Thromboembolism; Venous Thrombosis | 2003 |
Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Blood Transfusion; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Logistic Models; Odds Ratio; Time Factors | 2004 |
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Chronic Disease; Dalteparin; Glycine; Humans; International Normalized Ratio; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Uremia | 2005 |
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty; Aspirin; Azetidines; Benzylamines; Bleeding Time; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Enoxaparin; Europe; Female; Humans; Lower Extremity; Male; Middle Aged; Platelet Aggregation Inhibitors; South Africa; Thrombosis | 2006 |
6 other study(ies) available for dalteparin and melagatran
| Article | Year |
|---|---|
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Topics: Animals; Azetidines; Benzylamines; Dalteparin; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Infusions, Intravenous; Injections, Intravenous; Male; Piperidines; Rats; Rats, Wistar; Thrombin; Thrombophlebitis; Vena Cava, Inferior | 1997 |
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hirudins; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Thrombosis; Venae Cavae | 2002 |
Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action.
Topics: Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Male; P-Selectin; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Receptor, PAR-1; Receptors, Thrombin; Statistics as Topic; Thrombin | 2003 |
[The first oral thrombin inhibitor. Competition to heparins and marcumar?].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Glycine; Humans; Phenprocoumon; Placebos; Prodrugs; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2003 |
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.
Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Therapeutic Equivalency; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2004 |
Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Heart Valve Prosthesis Implantation; Random Allocation; Statistics, Nonparametric; Swine; Thromboembolism | 2007 |